ecancermedicalscience

Special Issue

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

28 Oct 2016
WH van Harten, VP Retèl

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership.

Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

Related Articles

Saran Green, Aida Santaolalla, Beth Russell, Gincy George, Harriet Wylie, Maria Monroy-Iglesias, Ailbhe Lawlor, Mark Minott, Annette Carty, Vernon Bailey, Tene Green, Zhane Peterson, Charlene Young, Mieke Van Hemelrijck
Chinelo C Nduka, Chizobam A Nweke, Runcie C W Chidebe, Candidus Nwakasi
Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka
Johnblack K Kabukye, Alice B S Nono Djotsa, Adedayo Joseph, Charles Muya, Benda N Kithaka, Mishka K Cira, Leshia Hansen, Annet Nakaganda